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The risk of patients with Hirschsprung’s disease later developing multiple endocrine neoplasia remains a matter of
concern. The multiple endocrine neoplasia 2–Hirschsprung’s disease association has been shown to cosegregate in
Hirschsprung’s disease patients with both short- and long-segment aganglionosis, although patients with long-
segment aganglionosis a to carry the greatest risk. The Hirschsprung’s disease–medullary thyroid carcinoma
relationship also appears to be bi-directional, and activation or suppression of the rearranged during transfection
gene appeared to vary over succeeding generations within the same family. Rearranged during transfection gene
variations are associated with both conditions. The cosegregation of Hirschsprung’s disease and multiple endocrine
neoplasia 2 is particularly interesting as it involves both ‘‘switch off’’ and ‘‘switch on’’ of the rearranged during
transfection proto-oncogene in the same patient. This cosegregation mostly relates to the cysteine-rich area on RET-
620 (the ‘‘Janus gene’’). The mechanism whereby rearranged during transfection influences gene activation in
multiple endocrine neoplasia 2 is complex, but genetic variations impair the rearranged during transfection tyrosine
kinase response to tyrosine kinase activation, thus appearing to dictate downstream signaling cascade responses.
Better understanding of the RET-620 relationship allows for a more cost-effective method of identifying those at
risk by focusing rearranged during transfection gene testing to this specific area as a ‘‘hot spot’’. The clinical
awareness of possible medullary thyroid carcinoma has led to timely intervention and early treatment of this
chemo- and radioresistant tumor with poor prognosis. Establishment of ‘‘risk’’ by genetic testing has become a
classic model of molecular medicine being integrated into patient care and offering rearranged during transfection-
directed prophylactic surgical management. In addition, novel approaches to treatment based on this genetic
knowledge have already shown early promise in randomized clinical trials.
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INTRODUCTION
Hirschsprung’s disease (HSCR), or aganglionic mega-
colon, occurs due to the congenital absence of parasym-
pathetic neuronal ganglia in a segment of the hindgut,
resulting in malfunction of the affected segment. The
condition presents as a common cause of intestinal ob-
struction in neonates, with an incidence of 1 in 5,000
(0.02%) live births and an overall risk to siblings of 4% (1–
3). A study of HSCR indicates several clear-cut associations
that are known or are suspected to be related to an
increased risk of HSCR. These include its recurrence in
families and the association with the major susceptibility
genes points convincingly to genetic factors in its multi-
factorial pathogenesis. The main susceptibility gene for
Hirschsprung’s disease is the RET (rearranged during
transfection) proto-oncogene tyrosine kinase which is
situated at chromosome 10q11.2.
There are early reports of associations between HSCR and
a number of associated anomalies related to neural cell
development. These include neuroblastoma (1), phaeochro-
mocytoma (1,4,5) and multiple endocrine neoplasia (MEN)
type 2 A and B syndromes (5–7), among others (1). Reports
on this relatively uncommon cosegregation of HSCR and
MEN2 in the same patient (6,8–20) exist because of the
common factor of the RET gene being associated with both
conditions (HSCR, MEN type 2 and medullary thyroid
carcinoma (MTC)). This is an extremely interesting observa-
tion, as it involves both gain and loss of function of the same
gene in the same patient.
Which patients are at risk?
The MEN–HSCR association has been shown to cosegre-
gate in HSCR patients with both short- and long-segment
aganglionosis (21). It seems to be particularly associated
with long-segment aganglionic segments, and Decker et al.
(21) reported a long aganglionic segment (L-HSCR) in seven
out of 13 patients (54%). Our experience is of total colonic
aganglionosis (TCA) in the index patient in all three families
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identified in our series (22). It therefore appears that
patients with long-segment HSCR carry the highest risk of
developing MTC and should have a detailed family his-
tory taken: the presence of a long-segment HSCR should
be an important selection criterion for gene testing in
HSCR.
It is important to explore this concept further in families
where HSCR and MTC coexist, as it will yield possible RET
gene associations and insights into possible molecular reasons
for the phenotypic expression. It is generally accepted that
aberrant RET protein synthesis, due to inactivating genetic
variations, lead to the congenital malformation of the enteric
nervous system (ENS) which we call Hirschsprung’s disease.
RET gene activation occurs in MEN2A.
The HSCR–MTC relationship also appears to be bi-
directional, and RET gene activation or suppression
appeared to vary over succeeding generations within the
same family (22). Butter et al. (23) reported a 50% incidence
of HSCR in 20 patients undergoing a prophylactic thyr-
oidectomy for RET-associated MTC risk (a RET C620
mutation). In one further reported case of familial MTC
(24) with a C620S point mutation, the MTC developed 12
years after surgical correction of HSCR in the child plus a
maternal MTC 7 years after the child’s birth. In our reported
series (22), MTC was detected in the parent 5 years after the
birth of the affected child.
Hirschsprung’s, MEN and the RET proto-oncogene
The RET proto-oncogene [10q11.22] is the major gene
involved in the pathogenesis of HSCR with causative loss-
of-function mutations being identified in more than 70%
of cases (25). In essence, the extracellular domain RET
mutations alter the protein and possibly its processing in the
endoplasmic reticulum (26). As a result, RET transport to
and its expression at the cell surface is decreased.
Multiple endocrine neoplasia also results from autoso-
mally dominant, inherited, highly penetrant germline RET
mutations that predispose patients to the development of
tumors in cells derived from neural crest origin. Of the more
than 25 RET proto-oncogene gene mutations which have
been described in association with MEN type 2 syndromes,
the most important are associated with the six cysteine
alleles of the extracellular portion of the RET proto-
oncogene in MEN2A.
RET is a vital gene which directs the migration,
proliferation and survival of the enteric neural crest-derived
cells of the enteric nervous system (ENS) during embry-
ogenesis. It is also responsible for the development of the
autonomic nervous system as well as for controlling kidney
development and spermatogenesis, among other functions.
Genetic mutation and/or variation may result in RET
malfunction, which has been associated with at least four
clinical conditions (HSCR, MEN type 2 syndromes (A and
B) and familial medullary thyroid carcinoma (FMTC)). In
HSCR, hypomorphic RET alleles may cause delayed
neuroblast migration and non-apoptotic cell death. This
causes ENS maldevelopment, resulting in aganglionosis
(HSCR) and other related conditions of the ENS.
The presence of a HSCR–MEN2 association raises the
question of which HSCR patients are at greatest risk and
should therefore be further investigated by RET gene
analysis. Hereditary MTC can, with rare exceptions, be
traced back in family trees (27) and the HSCR–MEN2
familial association may be missed because the MTC may
appear later in life without the connection being made. As a
result, the risk of HSCR patients later developing features of
an MEN2 syndrome (with MTC) is thought to be under-
evaluated. The risk of a future thyroid carcinoma remains a
matter of general concern in long-term HSCR management.
It is becoming clear that there is a need for screening in
order to determine which patients require RET gene
analysis as a means of determining risk.
The most frequently identified mutation responsible for
MEN2A involves the substitution of the cysteine amino acid
at position 634 (Cys634Arg or C634R) by the amino acid
arginine. However, point mutations in the cysteine-rich RET
area at the 620 position, along with some other RET gene
areas (e.g. C609, C611 and C618) have been reported as
being mostly associated with the HSCR–MEN2 phenotype.
By way of contrast, in .90% of MEN2B patients, the amino
acid methionine is replaced by threonine at position 918
(M918T) in the intracellular portion of the gene. There are
also a number of other RET variations that are associated
with thyroid cancers and familial medullary thyroid
carcinoma which may give rise to an overactive abnormal
RET protein.
The cosegregation of HSCR and MEN2 is particularly
interesting as it involves both a ‘‘switch off’’ and a ‘‘switch
on’’ of the gene in the same patient. Some remarkable family
lineages have been reported which demonstrate the occur-
rence of the two conditions in family lineages (17,22).
Which RET gene variations are important?
Like other receptor tyrosine kinases (RTKs), RET is made
up of at least three functional areas (extracellular, trans-
membrane and intracellular regions) which appear to have
specific roles in cellular function (28). It is interesting that, in
contrast to other susceptibility areas, the RET mutations
which have been identified as carrying both a risk for HSCR
as well as MEN2 approximate the transmembrane domain
of the gene (mostly C620R and occasionally C620S and
rarely C620W) (21). Although the majority of reports connect
these two conditions with point mutations in the cysteine-
rich RET-area at the 620 position, other RET gene areas (e.g.
C609, C611 and C618) have been reported as alternative
sites. The high frequency with which the C620 RET
mutation occurs in HSCR–MEN patients suggests the
concept of the so-called ‘‘Janus gene’’ mutation in this
position, which, like the Roman god of doorways, can face
in both directions (i.e. activation (MEN/MTC) and inactiva-
tion (HSCR)).
Our own studies (22) have shown the RET-620 cysteine
variations to be present in 2.5% of HSCR families (three out
of 118 families investigated), which is in keeping with other
reports (21). There was, however, an uncertain prevalence of
HSCR–MEN in related family members as not all could be
tested.
Studies have also shown that the closer mutations are to
the transmembrane domain, the higher their importance in
terms of the development of cellular proliferation and
tumor activation (29). A strong self-association has been
shown in the transmembrane portion of the gene (RET-TM),
which has been suggested as a possible explanation of the
oncogenic activation due to RET–cysteine mutations in
oncogenesis (29). This suggests an area that plays an
important role in MTC risk evaluation and may identify a
target area for novel therapeutic strategies.
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How does RET gene variation result in cellular
activation?
Because MEN2A relates mostly to the RET alleles at the
six cysteine positions in the extracellular domain of the
gene, it appears to induce a different set of downstream
signaling genes from that carrying the MEN 2B mutation.
The multidocking intracellular portion of the RET gene
where MEN2B RET variations are situated appears to be
vital to both tyrosine kinase function and downstream
signaling due to the number of signaling molecules that
interact there (e.g. Shc, Src, FRS2, IRS1, Gab1/2, and Enigma)
(30–32). It is therefore easier to understand how mutations
within this tyrosine-kinase rich region (e.g. in 95% of
MEN2B patients) alters the substrate specificity of RET
tyrosine kinase and results in gene activation.
The mechanism whereby RET influences gene activation
in MEN2A is more complex. Genetic variations impair the
RET tyrosine kinase response to tyrosine kinase activation,
thus appearing to dictate downstream signaling cascade
response (33). The induction of a disulfide-linked homo-
dimerization resulting from the cysteine-related mutations
within the extracellular portion of the RET proto-oncogene
promote dimer formation within the gene as covalent
receptor dimers are linked by disulfide bonds between
unpaired cysteines (34,35). It is known that the RET protein
targets a number of intracellular signaling cascades, includ-
ing the RAS-RAF-ERK1/2, PIK3-AKT, and STAT transcrip-
tion pathways (36). The activation of the MAPK and Ras/
ERK molecular signaling cascades involves grb2/mSOS
recruitment (37). In addition, recent studies have suggested
that the mammalian target of the rapamycin (mTOR)
intracellular signaling pathway is functionally activated in
MTC (especially in those with germline RET mutations)
(38), and that the role of the other downstream RET tyrosine
kinase signaling cascades (e.g. BRAF, RAS isoforms and PI3
kinase) is less certain.
How does the RET-620 relationship work?
Oncogenic RET mutations mostly occur de novo in
sporadic MTC, and it is now well accepted that RET gene
variations produce aberrant proteins which may bypass the
normal linking to growth factors outside the cell, most
probably triggering cells to grow and divide abnormally
and, in turn, promoting tumor formation. Ret activation
then promotes Ret-dimer formation and activation of
the tyrosine kinase outside of the normal ligand binding
system.
However, little is known of the actual mechanisms
whereby extracellular domain mutations (e.g. C620S) may
result in C-cell proliferation (39). Current understanding of
RET gene activation in MTC is that the gene is activated by
alterations in autophosphorylation, or alternatively by the
modification of the subcellular distribution of the active
kinase or the induction of unusual interactions with other
proteins (e.g. RET/PTC) (40).
It is possible that the MEN2A–HSCR connection repre-
sents a second alternative intracellular mechanism in the
pathogenesis of MTC (41). The less common codons C620,
C618 and C611 within exon 10 confer a weaker transforming
activity in vitro than exon 11 (C634) RET mutations (42). It
has been suggested that the MEN2A–HSCR connection
represents a second alternative intracellular mechanism
in the pathogenesis of MTC involving the endoplasmic
reticulum which has been shown to decrease cell surface
RET expression in HSCR (26). Changes in polarity in
MEN2A–HSCR may result in the unfolding of the RET
protein initially failing to achieve homeostasis via the
unfolded protein response (UPR) of the endoplasmic
reticulum, leading to apoptosis and HSCR. Subsequent
upregulation of the UPR may then induce changes which
allow gene activation, thus providing a growth advantage to
tumor cells.
Oncogenic RET mutations affect protein synthesis and
function, which then influence a number of downstream
molecular signaling pathways (43). Studies have demon-
strated that Ret influences the downstream phosphorylation
of the insulin receptor substrate-2 (IRS 2) with subsequent
activation of phosphatidylinositol 3 kinase (PI 3-kinase) and
protein kinase B (PKB/AKT) signaling pathways (44). In
addition, the induction of phosphorylation of SHC results in
growth factor receptor binding protein 2 (Grb-2) binding
and activation of the mitogen-activating protein (MAP)
kinase pathway (45). The resulting MAPK IRS-2, PI 3-kinase
and PKB/AKT activation could transduce the oncogenic Ret
signal to promote gene transcription, possibly through
activation of the jun/AP-1 transcription cascades (44).
Impact on treatment
This paper draws attention to the apparent genotype–
phenotype correlation which exists between RET and the
MEN2 syndromes (46,47). Clinical awareness of possible
MTC has led to timely intervention and early treatment of
this poor prognosis chemo- and radioresistant tumor.
Establishment of ‘‘risk’’ by genetic testing has become a
classic model of molecular medicine being integrated into
patient care. It is therefore fairly clear that RET gene
screening is of considerable value in familial screening, and
offering RET testing is considered best practice for the
clinical management of patients at risk of MEN2A and
MEN2B.
Gene mutation in the RET 620 position carries significant
risk of developing HSCR and/or MTC. In the interests of
cost-effectiveness, it may be part of a targeted investigation
of high-risk areas of the gene in HSCR patients at risk, thus
facilitating follow-up and future management. Genetic
screening is an extremely sensitive method of identifying
risk in MEN2 syndromes (¡98%) and prophylactic surgical
intervention may prevent the onset of the radio- and
chemoresistant MTC (48).
Better understanding of the RET-620 relationship would
also allow for a more cost-effective method of identifying
those at risk by focusing RET gene testing to this specific
area as a ‘‘hot spot’’. In addition, a number of attractive
targets are being identified which may be suitable for novel
therapeutic signaling pathway-specific drug design (49).
Novel approaches to treatment based on this genetic
knowledge have already resulted in randomized clinical
trials into the effectiveness of multi-kinase inhibitors such as
axitinib, sorafenib, motesanib, and XL-184. These have
shown early promise in selected cases which may soon
change the management of thyroid cancer (50).
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